MELISSA SHEPARD: Open Payments
NPI 1396565206 · HENSLEY, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$730 in 39 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $730
Food & beverage: $730
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $168 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $162 |
| AstraZeneca Pharmaceuticals LP | 5 | $87 |
| Axsome Therapeutics, Inc. | 4 | $86 |
| GlaxoSmithKline, LLC. | 5 | $81 |
| Dexcom, Inc. | 2 | $46 |
| Novo Nordisk Inc | 2 | $39 |
| Antares Pharma, Inc. | 1 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $14 |
Products named: CAPLYTA, UBRELVY, AIRSUPRA, Auvelity, TRELEGY ELLIPTA, Dexcom G6 Transmitter, VRAYLAR, XYOSTED.
Industry payments across AR — which companies pay providers there.
